SGMO Key Statistics, Chart & Performance
The current stock price of SGMO is 0.425 USD. In the past month the price decreased by -8.42%. In the past year, price decreased by -83.4%.
SGMO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About SGMO
Company Profile
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Richmond California, California and currently employs 183 full-time employees. The company went IPO on 2000-04-06. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Company Info
SANGAMO THERAPEUTICS INC
501 Canal Blvd.
Richmond California CALIFORNIA 94005 US
CEO: Alexander D. Macrae
Employees: 183
Phone: 15109706000
SANGAMO THERAPEUTICS INC / SGMO FAQ
What does SANGAMO THERAPEUTICS INC do?
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Richmond California, California and currently employs 183 full-time employees. The company went IPO on 2000-04-06. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Can you provide the latest stock price for SANGAMO THERAPEUTICS INC?
The current stock price of SGMO is 0.425 USD. The price decreased by -4.49% in the last trading session.
What is the dividend status of SANGAMO THERAPEUTICS INC?
SGMO does not pay a dividend.
How is the ChartMill rating for SANGAMO THERAPEUTICS INC?
SGMO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is SGMO stock listed?
SGMO stock is listed on the Nasdaq exchange.
Would investing in SANGAMO THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SGMO.
What is the next earnings date for SGMO stock?
SANGAMO THERAPEUTICS INC (SGMO) will report earnings on 2026-03-16, after the market close.
SGMO Technical Analysis
SGMO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SGMO. The financial health of SGMO is average, but there are quite some concerns on its profitability.
SGMO Financial Highlights
Over the last trailing twelve months SGMO reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 41.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -122.86% | ||
| ROE | -1744.5% | ||
| Debt/Equity | 0 |
SGMO Forecast & Estimates
For the next year, analysts expect an EPS growth of 34.33% and a revenue growth -5.05% for SGMO